Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDN3B1
|
|||
| Drug Name |
BIVV-003
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 1/2 | [1] | |
| Company |
Sangamo Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03653247) A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.